Daptomycin Injection, Powder, Lyophilized, For Solution
Pricing Report NDC 0143-9455-01
Current Package Pricing Information
The current wholesale acquisition cost for Daptomycin (NDC 0143-9455-01) is $13.41800 per EA. This benchmark price is based on the National Average Drug Acquisition Cost (NADAC) and has been effective since Apr 29, 2026.
As a a human prescription drug provided by Hikma Pharmaceuticals Usa Inc., this medication is distributed in a 1 VIAL, SINGLE-USE in 1 CARTON / 7 mL in 1 VIAL, SINGLE-USE configuration. The pricing data is derived from C/I - Chain or Independent Pharmacy surveys, reflecting the actual invoice prices paid by community pharmacies to drug wholesalers.
NADAC Pricing Summary
NADAC pricing snapshot for this package NDC
Acquisition Cost $13.41800 Per EA
The NADAC was calculated based on package size.
The CMS Covered Outpatient File drug category type of S/I/N (Single Source/Innovator/Non-Innovator) has not been applied. Most S/I drugs with the same strength, dosage form and route of administration were grouped together for the purpose of the NADAC calculation and N drugs were also grouped together. In some cases, however, in calculating a NADAC, the CMS S/I/N designation was not applied when the state Medicaid brand or generic payment practices for these drugs generally differed from the CMS Covered Outpatient File designation.
Historical Pricing Trends & Acquisition Cost Benchmarks
The current wholesale price for (NDC ) is based on the most recent federal survey data. As this is a newer entry or has a stable pricing model, the chart below reflects the current established benchmark of $13.41800 per EA.
| Date | Unit Price | Unit | Source | Method | Rate |
|---|---|---|---|---|---|
| Apr 29, 2026 | $13.41800 | EA | C/I - Chain or Independent Pharmacy | Code 4, 5, 6 | G - Generic |
Pricing Methodology Legend
- Code 4: The NADAC was carried forward from the previous file.
- Code 5: The NADAC was calculated based on package size.
- Code 6: The CMS Covered Outpatient File drug category type of S/I/N (Single Source/Innovator/Non-Innovator) has not been applied. Most S/I drugs with the same strength, dosage form and route of administration were grouped together for the purpose of the NADAC calculation and N drugs were also grouped together. In some cases, however, in calculating a NADAC, the CMS S/I/N designation was not applied when the state Medicaid brand or generic payment practices for these drugs generally differed from the CMS Covered Outpatient File designation.
Understanding NADAC Pricing Data
The National Average Drug Acquisition Cost (NADAC) is compiled by the Centers for Medicare and Medicaid Services (CMS). This data is derived from random monthly surveys of more than 60,000 pharmacies across all 50 states.
Important Price Distinction:
The prices listed on this page represent the wholesale invoice price paid by pharmacies to acquire the drug. This is NOT the retail price paid by consumers at the pharmacy counter. Final patient costs typically include pharmacy markups, professional dispensing fees, and insurance adjustments.
NADAC Pricing Data Last Updated on: July 08, 2026
